Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$213.00K$213.00Kderived— vs Q4 2023 Net Income-$3.37M-$3.37MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,387,000N/M Operating Cash Flowderived-$3,932,000N/M Free Cash Flowderived-$3,932,000N/M Margins · derivedOperating margin-1590.1%
Net margin-1584.0%
ended Dec 31, 2024 · filed Apr 15, 2025 · 105 d after period end